Compare ON Holding AG (ONON) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Summit Therapeutics Inc — how do they compare? ON Holding AG trades at $35.05 (market cap $11.38B), while Summit Therapeutics Inc trades at $17.6 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and ON Holding AG is more actively traded (13,732,872 versus 6,173,057). Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and Summit Therapeutics Inc for 16 Days on average.
| ONON | SMMT | |
|---|---|---|
Market Cap | $11.38B | $13.71B |
Volume | 13,732,872 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $26.38 |
52-Week Low | $26.76 | $12.43 |
Typical Hold Time | 22 Days | 16 Days |
Enterprise Value | $10.54B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON stock trades at $35.09, up 5.63% with strong bullish momentum. The company demonstrates robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 versus $0.42 expected. Recent investor day announcements of a $1 billion buyback program and ambitious 2029 targets have fueled positive sentiment. Technical indicators show bullish moving averages but overbought RSI conditions.
Outlook remains positive with analyst consensus at $42.26 target (20% upside) and 74% buy ratings. Key opportunities include premium store expansion and new sports categories, while risks involve execution on growth targets and competitive pressures in athletic footwear. The stock's current valuation at 24x P/E reflects growth expectations.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
